Acumen Pharmaceuticals Completes Enrollment of ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer's Disease

Stock Information for Acumen Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Acumen Pharmaceuticals Inc.

Acumen Pharmaceuticals and JCR Pharmaceuticals Enter Strategic Collaboration, Option and License Agreement to Develop Enhanced Brain Delivery(TM) Therapy for Alzheimer's Disease
Acumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer's Association International Conference (AAIC®) 2025
Acumen Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Highlights
Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference
Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025
Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting
Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2024 and Business Highlights

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.